CARMEL, Ind., Feb. 27, 2024 -- NeurAxis, Inc. (NYSE American: NRXS), ("NeurAxis," or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced that...
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference
PONTE VEDRA, Fla., Feb. 26, 2024 -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood...
Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)
NEW YORK, Feb. 22, 2024 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that the Company has launched a Healthcare Setting Locator (Locator) on the...
Modular Medical Announces Closing of $10 Million Public Offering
SAN DIEGO, CA / February 21, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development stage insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, announced...
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
CUPERTINO, Calif., Feb. 20, 2024 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Feb. 16, 2024 -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously...
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023
Conference Call Scheduled for Wednesday, February 28, 2024 at 9:00 AM ETPORTLAND, Maine, Feb. 16, 2024 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven...
Modular Medical Announces Pricing of $10 Million Public Offering
SAN DIEGO, CA / February 15, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development stage insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today...
Modular Medical Announces Proposed Public Offering
SAN DIEGO, CA / February 15, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical"), a development stage insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced that it...
Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change
DUBLIN, Ireland, Feb. 15, 2024 -- Trinity Biotech Plc.(NASDAQ: TRIB) (the "Company") today announced that it has finalized the effective date of its ratio change of its American depositary shares ("ADSs") from one (1) ADS representing four (4) Class A ordinary shares...